An observational study in Stargardt Disease, Stargardt Macular Degeneration and Stargardt Macular Dystrophy, sponsored by Splice Bio. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Splice Bio · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the long-term safety of subretinal SB-007 administration in subjects with Stargardt Disease Type 1 (STGD1).
This is a multicenter study which will follow subjects over a 164-week period after completion of an antecedent SB-007 interventional trial.
68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.
This study's planned enrollment of 55 is close to the median of 50 across 25 observational studies indexed under Stargardt Disease.
Browse Stargardt Disease studies →Splice Bio is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All subjects who were previously enrolled in and were treated with SB-007 in an antecedent SB-007 interventional trial and who meet the eligibility criteria for this study will be invited to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for study participation, subjects must meet the following criteria:
Exclusion Criteria:
Subjects must be excluded from participating in the study if they:
1. Are unwilling to follow the requirements of the LTFU study, including study visits and assessments.
All subjects previously treated with SB-007
Drug: No new intervention
This is an observational long-term follow-up (LTFU) study of subjects with STGD1 who were previously treated with SB-007 in an antecedent SB-007 interventional trial. There is no new intervention involved in this LTFU study.
Long-term safety of SB-007
Long-term safety of SB-007, as assessed by all ocular and non-ocular AEs
Time frame: 164 weeks
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Dec 2035, 108 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Splice Bio